Latest News

eyonis LCS is a Software as a Medical Device that uses AI to assist clinicians in detecting and diagnosing lung cancer during screening workflows.

Under the agreement, MiRecule will combine its NAVIgGator platform, which is designed to support the development of precision RNA medicines, with RBBL’s expertise in peptide discovery, development, and manufacturing.

BYPHAR is designed to simplify raw material selection while helping manufacturers meet increasingly stringent quality and regulatory requirements throughout the development and production process.

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.

The partnership combines Budenheim’s manufacturing expertise with Brenntag’s biopharma services and distribution network.

Under the agreements, MSD will work with Aspen Pharmacare in South Africa, Quality Chemicals Industries Limited (QCIL) in Uganda and Universal Corporation Limited (UCL) in Kenya.

The initiative comes as scientists intensify efforts to address a major Bundibugyo ebolavirus outbreak, with cases rising rapidly in the Democratic Republic of the Congo (DRC).

The clinical trial will assess SIL204, an investigational treatment developed by Silexion using small interfering RNA (siRNA) technology.